HSHHSH Health Technology Supplier Hub
Home › Suppliers › Smith & Nephew › Risk

Smith & Nephew: risk summary

Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.

Financial

Latest full-year results from official filings.

FY2025 revenue $6.16bn (+6.1%); operating margin 12.9%; net income $625.0m.

Net debt $2.76bn including leases.

Researched 8 Nov 2026

Adverse media

Credible news about incidents, disputes, legal action or restructuring in the last 24 months.

Nov 2026: Smith & Nephew cut its 2026 guidance, citing weaker US Orthopaedics growth, and said earlier talks with Johnson & Johnson on a possible deal involving its Orthopaedics division had ended; it is still exploring options for that division.

Researched 10 Nov 2026

Cyber & information governance

Data breaches, cyber incidents, regulator action and assurance status.

Feb 2026: the 0apt ransomware group claimed to have taken data from Smith & Nephew (UK), according to a threat-intelligence site; the claim is unverified and no company confirmation was found. NHS DSPT status not yet checked.

Researched 10 Nov 2026

Regulatory & clinical safety

Recalls, safety notices, regulator action and clinical safety concerns.

Sep 2026: FDA Class 2 recall of an EVOS proximal tibia plate for incorrect labelling. Mar 2026: Class 2 recall of a lot of TRIGEN humeral nails made without some distal holes, which the notice says could lead to revision surgery.

Researched 10 Nov 2026

Contract performance

Contract delivery, go-lives, terminations and disputes.

No notable NHS contract awards, terminations or customer disputes involving Smith & Nephew found in HSH's search of the last 24 months.

Researched 10 Nov 2026